These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
48. Insulin-like growth factor pathway: a link between androgen deprivation therapy (ADT), insulin resistance, and disease progression in patients with prostate cancer? Aggarwal RR; Ryan CJ; Chan JM Urol Oncol; 2013 Jul; 31(5):522-30. PubMed ID: 21658978 [TBL] [Abstract][Full Text] [Related]
49. Drug insight: role of the androgen receptor in the development and progression of prostate cancer. Taplin ME Nat Clin Pract Oncol; 2007 Apr; 4(4):236-44. PubMed ID: 17392714 [TBL] [Abstract][Full Text] [Related]
51. The role of the androgen receptor in the development of prostatic hyperplasia and prostate cancer. Chatterjee B Mol Cell Biochem; 2003 Nov; 253(1-2):89-101. PubMed ID: 14619959 [TBL] [Abstract][Full Text] [Related]
52. [Molecular mechanisms involved in hormone resistance of prostate cancer]. Cabrespine A; Guy L; Chollet P; Debiton E; Bay JO Bull Cancer; 2004 Oct; 91(10):747-57. PubMed ID: 15556875 [TBL] [Abstract][Full Text] [Related]
53. Androgen receptor inhibition suppresses anti-tumor neutrophil response against bone metastatic prostate cancer via regulation of TβRI expression. Alsamraae M; Costanzo-Garvey D; Teply BA; Boyle S; Sommerville G; Herbert ZT; Morrissey C; Dafferner AJ; Abdalla MY; Fallet RW; Kielian T; Jensen-Smith H; deOliveira EI; Chen K; Bettencourt IA; Wang JM; McVicar DW; Keeley T; Yu F; Cook LM Cancer Lett; 2023 Nov; 579():216468. PubMed ID: 37940068 [TBL] [Abstract][Full Text] [Related]
54. The basic biochemistry and molecular events of hormone therapy. Mostaghel EA; Montgomery RB; Lin DW Curr Urol Rep; 2007 May; 8(3):224-32. PubMed ID: 17459272 [TBL] [Abstract][Full Text] [Related]
55. A novel selective androgen receptor modulator (SARM) MK-4541 exerts anti-androgenic activity in the prostate cancer xenograft R-3327G and anabolic activity on skeletal muscle mass & function in castrated mice. Chisamore MJ; Gentile MA; Dillon GM; Baran M; Gambone C; Riley S; Schmidt A; Flores O; Wilkinson H; Alves SE J Steroid Biochem Mol Biol; 2016 Oct; 163():88-97. PubMed ID: 27106747 [TBL] [Abstract][Full Text] [Related]
56. Neuroendocrine differentiation in prostate carcinoma: focusing on its pathophysiologic mechanisms and pathological features. Alberti C G Chir; 2010; 31(11-12):568-74. PubMed ID: 21232206 [TBL] [Abstract][Full Text] [Related]
57. Role of coordinated molecular alterations in the development of androgen-independent prostate cancer: an in vitro model that corroborates clinical observations. Shi Y; Chatterjee SJ; Brands FH; Shi SR; Pootrakul L; Taylor CR; Datar R; Cote RJ BJU Int; 2006 Jan; 97(1):170-8. PubMed ID: 16336351 [TBL] [Abstract][Full Text] [Related]
58. Immunomagnetic quantification of circulating tumor cells as a prognostic factor of androgen deprivation responsiveness in patients with hormone naive metastatic prostate cancer. Okegawa T; Nutahara K; Higashihara E J Urol; 2008 Oct; 180(4):1342-7. PubMed ID: 18707699 [TBL] [Abstract][Full Text] [Related]